Baxter International Inc. (BAX)
| Market Cap | 9.23B |
| Revenue (ttm) | 11.02B |
| Net Income (ttm) | -341.00M |
| Shares Out | 514.06M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | 8.16 |
| Dividend | $0.68 (3.79%) |
| Ex-Dividend Date | Aug 29, 2025 |
| Volume | 11,321,883 |
| Open | 17.87 |
| Previous Close | 17.94 |
| Day's Range | 17.47 - 18.08 |
| 52-Week Range | 17.47 - 37.74 |
| Beta | 0.61 |
| Analysts | Hold |
| Price Target | 27.00 (+50.42%) |
| Earnings Date | Oct 30, 2025 |
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technolog... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for BAX stock is "Hold." The 12-month stock price target is $27.0, which is an increase of 50.42% from the latest price.
News
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in Baxter International, Inc. Lawsuit – BAX
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during th...
Watch These Stocks Falling 10% Or More
Fiserv (FI) leads decliners with a 49% drop, driven by leadership turmoil, weak consumer spending, and a downgraded quant rating to 'Strong Sell.' Alexandria Real Estate (ARE) and Robert Half (RHI) su...
BAX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Baxter To Contact Him Directly To Discuss Their Options
Don't Write Off Baxter Just Yet
Baxter International (BAX) trades at a 20-year low after operational missteps, a failed Hill-Rom acquisition, and ongoing execution issues. Despite recent setbacks, BAX still generates solid margins a...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Baxter To Contact Him Directly To Discuss Their Options If you suf...
Baxter Trims Annual Outlook Again, Stock Hits 52-Week
Baxter International Inc. (NYSE:BAX) stock hit a 52-week low on Thursday, after the company again lowered its 2025 guidance.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
Baxter International Inc. (BAX) Q3 2025 Earnings Call Transcript
Baxter International Inc. ( BAX) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Kevin Moran Andrew Hider - CEO, President & Director Joel Grade - Executive VP & CFO Conferenc...
Medical products maker Baxter cuts annual profit forecast on persistent hurricane impact
Baxter International on Thursday trimmed its forecasts for adjusted annual profit and revenue growth, after missing third-quarter revenue estimates due to persistent impact from hurricane-related disr...
Baxter Reports Third-Quarter 2025 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. “I joined Baxter because it's a global healthcare...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
Artisan Partners Q3 2025 Position Updates
Shares of Centene plunged after the company withdrew its 2025 guidance, driven by higher-than-expected market acuity on the ACA marketplaces and elevated Medicaid cost trends. Align Technology is a me...
BAXTER INTERNATIONAL INC. (NYSE: BAX) DEADLINE ALERT Bernstein Liebhard LLP Reminds Baxter International Inc. Investors of Upcoming Deadline
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Baxter International Inc. (NYSE: BAX)? Did you purchase your shares between February 23, 2022 and ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in Baxter International, Inc. Lawsuit - BAX
NEW YORK , Oct. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during the c...
BAX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
BAX STOCK NOTICE: Baxter International Inc. Investors with Losses may have been Affected by Fraud – Contact BFA Law before December 15 Lawsuit Deadline
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Baxter International Inc. (NYSE: BAX) a...
BAXTER INTERNATIONAL INC. (NYSE: BAX) INVESTOR ALERT Investors With Large Losses in Baxter International Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
BAX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options If you suffered losses in Ba...
Baxter to Host Third-Quarter 2025 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its third-quarter 2025 financial results on Thursday, O...
Baxter is First Manufacturer to Achieve Gold Resiliency Badge for IV Solutions, Nutrition Solutions and Premix Drugs from Healthcare Industry Resilience Collaborative (HIRC)
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has been awarded a Gold Level Resiliency Badge from the Healthcare Ind...
Baxter Launches Welch Allyn Connex 360 Vital Signs Monitor to Advance Connected Patient Monitoring
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today launched the Welch Allyn Connex 360 Vital Signs Monitor, its next generation patient mon...
Is Now The Time To Buy Baxter Stock?
Baxter stock (NYSE: BAX), a healthcare company, has seen its stock decline by 14% over the past month. This drop followed a disappointing earnings report where the company also reduced its full-year g...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Hospital Product Maker Baxter Stock Plunges On Trimmed Annual Outlook
Q2 adjusted EPS was $0.59, matching guidance but slightly below the $0.61 Street estimate. FY25 EPS forecast lowered to $2.42–$2.52 vs. prior range of $2.47–$2.55.